GSK to acquire Canada's 35Pharma for $950m
By Iain Gilbert
Date: Wednesday 25 Feb 2026
(Sharecast News) - Drugmaker GSK has agreed to acquire Canadian clinical-stage biopharmaceutical firm 35Pharma for $950m in cash.
GSK said on Wednesday that the acquisition includes 35Pharma's HS235, a potential best-in-class investigational medicine that has completed phase I healthy volunteer clinical trials, with studies to start imminently in pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction.
The FTSE 100-listed firm noted that the global market for PH therapies was forecast to reach $18bn by 2032, with activin signalling inhibitors expected to account for 50% of this.
GSK added that transaction was subject to customary conditions, including applicable regulatory agency clearances under the Hart-Scott-Rodino Act in the US and the Competition Act in Canada, along with a filing under the Investment Canada Act.
Reporting by Iain Gilbert at Sharecast.com
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN